Evidence map›Paper›PMID 38766034›Full record

ArticleResearch square2024

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia using Patient-Reported Outcomes: Protocol for a Prospective Observational Study.

Alexander P Glaser, Abigail R Smith, Dacey Maglaque, Brian T Helfand, Rowida Mohamed, Hosanna An, Melissa Marquez, Pooja Talaty, Padraig Carolan, Aaron M Geller and 3 more

Registry-linked trialAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05898932 (Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05898932 recruitingnot on this map

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

TypeobservationalSponsorNorthwestern UniversityRan2023 to 2027Enrolled300ConditionsBenign Prostatic HyperplasiaArmsMedical Management, Surgical Management
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alexander P GlaserNorthShore University HealthSystem.
Abigail R SmithNorthwestern University.
Dacey MaglaqueNorthShore University HealthSystem.
Brian T HelfandNorthShore University HealthSystem.
Rowida MohamedUniversity of Chicago.
Hosanna AnUniversity of Chicago.
Melissa MarquezUniversity of Chicago.
Pooja TalatyNorthShore University HealthSystem.
Padraig CarolanNorthwestern University.
Aaron M GellerNorthwestern University.
Francesca R FarinaUniversity of Chicago.
Sally E JensenNorthwestern University.
James W GriffithUniversity of Chicago.

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported OutcomesR01DK130963 · NIDDK · UNIVERSITY OF CHICAGO · PI Alexander Paul Glaser, James William Griffith · 2022 to 2026
$3.3M
NCATS NIH HHS UL1 TR001422NIDDK NIH HHS R01 DK130963
6 · The paper itself

Abstract

Background: Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) significantly impact quality of life among older men. Despite the prevalent use of the American Urological Association Symptom Index (AUA-SI) for BPH, this measure overlooks key symptoms such as pain and incontinence, underscoring the need for more comprehensive patient-reported outcome (PRO) tools. This study aims to integrate enhanced PROs into routine clinical practice to better capture the spectrum of LUTS, thereby improving clinical outcomes and patient care. Methods: This prospective observational study will recruit men with LUTS secondary to BPH aged ≥ 50 years from urology clinics. Participants will be stratified into medical and surgical management groups, with PRO assessments scheduled at regular intervals to monitor LUTS and other health outcomes. The study will employ the LURN Symptom Index (SI)-29 alongside the traditional AUA-SI and other non-urologic PROs to evaluate a broad range of symptoms. Data on comorbidities, symptom severity, and treatment efficacy will be collected through a combination of electronic health records and PROs. Analyses will focus on the predictive power of these tools in relation to symptom trajectories and treatment responses. Aims are to: (1) integrate routine clinical tests with PRO assessment to enhance screening, diagnosis, and management of patients with BPH; (2) examine psychometric properties of the LURN SIs, including test-retest reliability and establishment of clinically meaningful differences; and (3) create care-coordination recommendations to facilitate management of persistent symptoms and common comorbidities measured by PROs. Discussion: By employing comprehensive PRO measures, this study expects to refine symptom assessment and enhance treatment monitoring, potentially leading to improved personalized care strategies. The integration of these tools into clinical settings could revolutionize the management of LUTS/BPH by providing more nuanced insights into patient experiences and outcomes. The findings could have significant implications for clinical practices, potentially leading to updates in clinical guidelines and better health management strategies for men with LUTS/BPH. Trial registration: This study is registered in ClinicalTrials.gov (NCT05898932).

Indexed as

Lower urinary tract symptomsPatient Reported Outcome MeasuresProstatic HyperplasiaQualitative ResearchSymptom Assessment

Identifiers

PMID38766034
PMCPMC11100908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.